NuVasive (NUVA) Gets a Buy Rating from BTIG

By Ryan Adsit

BTIG analyst Ryan Zimmerman maintained a Buy rating on NuVasive (NUVAResearch Report) on June 27 and set a price target of $65. The company’s shares closed on Friday at $58.54.

According to, Zimmerman is a top 100 analyst with an average return of 42.1% and a 67.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NuVasive with a $63 average price target.

See today’s analyst top recommended stocks >>

NuVasive’s market cap is currently $3.04B and has a P/E ratio of 62.93. The company has a Price to Book ratio of 3.61.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.